DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Comparison of Beta-blocker Versus Angiotensin Receptor Blocker for Suppression of Aneurysm Expansion in Patients With Small Abdominal Aortic Aneurysm and Hypertension (BASE Trial)

Information source: Yonsei University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Small Abdominal Aortic Aneurysm

Intervention: Beta-blocker-Atenolol 50mg, PO(peroral), Once daily (Drug); Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Yonsei University

Overall contact:
Dong-Hoon Choi, MD, Phone: 82 2 2228 8449, Email: cdhlyj@yuhs.ac

Summary

Various medical therapies have been proposed to prevent abdominal aortic aneurysm expansion. However, there have been very few randomized clinical trials to support use of any of these treatments. Several animal studies and observational reports suggest that ARBs can be useful in reducing abdominal aortic aneurysm (AAA) growth. However, so far, ARBs have not been evaluated in a randomized clinical trial. Therefore, the purpose of the study is to evaluate the effect of valsartan, an ARB, on annual growth rate in comparison with atenolol, a beta-blocker. Our hypothesis is that valsartan is superior to atenolol in the suppression of the aneurysm growth at 12 months. The BASE trial is designed as a investigator-initiated, multi-center, randomized controlled open-label trial. Patients with small AAA (aorta diameter <5cm) will be randomized 1: 1 either to valsartan or to atenolol group. Randomization will be stratified by the AAA size (max. diameter >4 cm or ≤4 cm). Patients will receive either valsartan (daily dose 80 mg or more) or atenolol (daily dose 50 mg or more) for 12 months. A CT scan will measure the maximal diameter of AAA at baseline and 12 months. The annual growth of AAA will be compared between the valsartan and the atenolol group.

Clinical Details

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Annual aneurysm growth of abdominal aortic aneurysm

Eligibility

Minimum age: 20 Years. Maximum age: 90 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age ≥20years

- Abdominal aortic aneurysm with maximal diameter less than 5cm

- Hypertension

- Patient with signed informed consent

Exclusion Criteria:

- Saccular type aneurysm, inflammatory aneurysm, or infected aneurysm

- Aortic dissection

- Planned surgery or endovascular therapy for abdominal aortic aneurysm within 1 year

- Previous aorta surgery or endovascular therapy

- Contraindications to Beta-blocker or ARB (allergic reactions, asthma, severe

bradycardia, angioedema, hyperkalemia)

- Allergic reaction to contrast dye

- Known genetic aorta disease or autoimmune or connective tissue disease: Marfan

syndrome, Shprintzen-Goldberg syndrome, Loeys-Dietz syndrome, Takayasu's arteritis, Behcet's disease

- Pregnancy

- Life expectation <1 year

- Renal failure (serum Cr >2. 0 mg/dL)

- Liver disease (ALT or AST > 3 x upper limit) or liver cirrhosis (Child B or C)

- Malignancy requiring surgery or chemotherapy within 1 year after enrollment

- Status post transplantation or chronic inflammatory disease requiring immune

suppressive drugs over 4 weeks

Locations and Contacts

Dong-Hoon Choi, MD, Phone: 82 2 2228 8449, Email: cdhlyj@yuhs.ac

Severance Hospital, Seoul 120-752, Korea, Republic of; Recruiting
Dong-Hoon Choi, MD, Phone: 82 2 2228 8449, Email: cdhlyj@yuhs.ac
Additional Information

Starting date: January 2013
Last updated: July 24, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017